Call Today: 800-889-3898
Submit your Raptiva claim details for a free, no obligation case review
Get Started:
Genentech, Inc. is the corporation that manufactures Raptiva® (generic name, efalizumab), a relatively new treatment for moderate-to-severe psoriasis. As a prescription-only once-weekly injection, Raptiva was approved by the Food and Drug Administration (FDA) in 2003, but it has come under recent scrutiny due to its connection to life-threatening infections, including:
Based in San Francisco, Genentech is a huge company. In March 2009, Genentech executives stated that the sales of another Genentech product, the cancer drug Avastin, are expected to quadruple by the year 2015 to $10 billion. Genentech develops and provides many other drugs, including:
Genentech was founded in 1976 and went public in 1980. It marketed the first recombinant DNA drug — human insulin — in 1982, licensed to the pharmaceutical giant Eli Lilly and Co. In 2003, Genentech obtained the FDA's approval for Raptiva as a psoriasis treatment for adult candidates for systemic therapy or phototherapy.
Genentech describes Raptiva as "the first biologic therapy designed to provide continuous control of chronic moderate-to-severe plaque psoriasis and can be self-administered by patients as a single, once-weekly, subcutaneous injection." Raptiva medication for self-injections comes in packages that include the necessary syringes and needles (disposable).
In February 2009, the FDA issued a warning emphasizing the possibility of contracting PML and other opportunistic infections from Raptiva treatment. The reports of deaths and serious illnesses among Raptiva patients are being taken very seriously by the FDA, and it is possible that Raptiva will be removed from the market in the U.S. Raptiva drug was pulled from the market in Europe in February 2009 in response to the deaths and injuries linked to the drug.
The recent FDA Raptiva warning also noted that:
If you or a loved one has been injured after taking Raptiva or another drug manufactured by Genentech, you may be eligible to recover compensation for your losses. To schedule a private, no cost consultation with an experienced Raptiva attorney who will evaluate your case and ensure you receive the compensation you are entitled to, please contact us today.
The U.S. Food and Drug Administration (FDA) announced a voluntary Raptiva recall, April 8, 2009. The Psoriasis drug’s manufacturer, Genentech, announced the voluntary Raptiva recall and has begun phasing the drug off the U.S. market. R...
Copyright © 2001 - 2009 Online Lawyer Source | Legal Marketing Site Designed by eJustice